CA AB575

Requires individual and group health care service plans and insurance policies issued, amended, or renewed on or after January 1, 2026, to cover at least one FDA-approved glucagon-like peptide-1 receptor agonist (GLP-1RA) for obesity treatment or prevention without prior authorization

Mandates coverage for intensive behavioral therapy for obesity treatment without prior authorization

Prohibits coverage criteria for anti-obesity medications from being more restrictive than FDA-approved indications for those treatments

Allows health plans and insurers to apply utilization management for medical necessity determinations, but only if applied the same way as for other covered conditions

Exempts specialized dental-only, vision-only, and Medicare supplement contracts from these requirements